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Abstract
Objective. Ciclosporin and MTX are used in idiopathic inflammatory myopathies (DM and PM) when
patients incompletely respond to glucocorticoids. Their effectiveness is unproved in randomized controlled
trials (RCTs). We evaluated their benefits in a placebo-controlled factorial RCT.
Methods. A 56-week multicentre factorial-design double-blind placebo-controlled RCT compared steroids
alone, MTX (1525 mg weekly) plus steroids, ciclosporin (15 mg/kg/day) plus steroids and all three treatments.
It enrolled adults with myositis (by Bohan and Peter criteria) with active disease receiving corticosteroids.
Results. A total of 359 patients were screened and 58 randomized. Of the latter, 37 patients completed 12
months of treatment, 7 were lost to follow-up and 14 discontinued treatment. Patients completing 12
months of treatment showed significant improvement (P<0.001 on paired t-tests) in manual muscle
testing (14% change), walking time (22% change) and function (9% change). Intention to treat and
completer analyses indicated that ciclosporin monotherapy, MTX monotherapy and ciclosporin/MTX com-
bination therapy showed no significant treatment effects in comparison with placebo.
Conclusion. Neither MTX nor ciclosporin (by themselves or in combination) improved clinical features in
myositis patients who had incompletely responded to glucocorticoids.
Trial Registration: International Standard Randomized Controlled Trial Number Register; http://www.
controlled-trials.com/; ISRCTN40085050
Key words: myositis and muscle disease, rheumatic diseases, DMARDs therapies, immunosuppressant thera-
pies, clinical trials and methods, basic and clinical sciences, quality of life, psychology and social phenomena.
Rheumatology key messages
. Patients with active inflammatory myositis taking oral steroids improve over time.
. There is no evidence that adding MTX or ciclosporin benefits patients with active inflammatory myositis taking
oral steroids.
. In patients with active inflammatory myositis taking oral steroids, there is no evidence that combining MTX and
ciclosporin is beneficial.
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Introduction
Idiopathic inflammatory myositis (IIM) spans dermatomyo-
sitis and polymyositis. Initial treatment currently focuses
on glucocorticoids, although there is little confirmatory
randomized controlled trial (RCT) evidence [1]. Immune-
modulating drugs are used when glucocorticoid-treated
IIM patients have persisting disease or need steroid-
sparing agents. RCT evidence supports giving these
patients IVIG [2]. Open-label studies and case series sug-
gest potential benefits from biologics (like rituximab) and
conventional immunosuppressive agents [3]. Currently,
RCT evidence for any of these treatments in adults is in-
conclusive or negative [4].
We addressed this uncertainty in a factorial RCT as-
sessing two conventional immunosuppressive drugs.
MTX and ciclosporin were used (either singly or in
combination) in addition to glucocorticoids in IIM treat-
ment. These therapies were selected because of positive
observational evidence [3], differing modes of action, and
positive findings in RA [5]. The trial studied glucocorticoid-
treated patients with incomplete therapeutic responses
and evidence of ongoing active disease.
Methods
Design
A 56-week double-blind 22 factorial RCT randomized
patients to receive MTX (active or placebo) and ciclos-
porin (active or placebo).
Patients
Male and female adults attending hospital outpatient
clinics were enrolled.
Inclusion criteria: (i) definite IIM by Bohan and Peter
criteria [6]; (ii) receiving glucocorticoids; (iii) active disease
(muscle weakness 4/5 by manual muscle strength testing
(MMT) in two or more muscle groups and functional deficit
of one or more levels in one or more area of activities of
daily living (using the functional rating scale); and (iv) will-
ing and able to give informed consent.
Exclusion criteria: (i) under 18 years; (ii) inclusion body
myositis and muscular dystrophies; (iii) unresponsive to
60 mg/day prednisolone for at least 4 weeks; (iv) family
history of neuromuscular disease; (v) other serious dis-
orders or contraindications (see supplementary Table
S1, available at Rheumatology Online).
Previous immunosuppressive treatments
Previous immunosuppressive treatments had been ad-
ministered to 18 patients; of these, 8 had received MTX
for a median of 2.1 years, and 2 had received ciclosporin
for a median of 1.4 years. Patients had stopped these
immunosuppressive treatments for a median of 0.33.6
years before entering the trial (see supplementary Table
S2, available at Rheumatology Online).
The South-East Multicentre Research Ethics Committee
approved Second Line Agents in Myositis (SELAM)
(MREC Ref: 00/1/73). All enrolled patients gave written
informed consent. The trial was registered with the UK
Clinical Research Network and other relevant organiza-
tions (EudraCT number: 2004-001067-21; ISRCTN:
40085050; NIHR Porfolio ref: 2672).
Treatments
MTX was given initially at 7.5 mg/week, increasing every 2
weeks by 2.5 mg to 15 mg/week. If there was persistent
active disease, the dosage was increased by the super-
vising doctor to a maximum of 25 mg/week. Ciclosporin
(microemulsion) was initiated at 1 mg/kg/day then
increased where tolerated to a target of 5 mg/kg/day. If
there was persistent active disease, the dosage was fur-
ther increased to 10 mg/kg/day at the clinician’s discre-
tion. Matched placebos were increased similarly. All
patients remained on steroids, and the dosage of steroids
was adjusted by the local researcher according to disease
activity.
Patients continued analgesics (paracetamol or co-prox-
amol) or NSAIDs at standard dosages if needed. Other
treatments (e.g. antihypertensives) were continued as
needed. All patients received folic acid (5 mg/week).
Patients on high-dose CS received appropriate bone
protection.
Outcomes
Patients were assessed at baseline and 12, 28, 40 and 56
weeks. The primary outcome measure was MMT at 56
weeks [7]. Secondary outcome assessments included
the functional rating scale (FRS) [8], 30-m walking time
(WT), creatine kinase (normal laboratory range up to
150 IU/ml), ESR (normal laboratory range up to 20 mm/h),
treatment withdrawals, and adverse reactions.
Sample size
Sample size was based on previous studies suggesting
that MTX and ciclosporin improve MMT scores by 10%
[4]. As RA trials show that ciclosporin and MTX have addi-
tive effects, we used a factorial 2 2 design [5]. Assuming
MTX and ciclosporin groups had effect sizes of 1 (10%
improvement with 10% S.D. %), an adjusted effect size
based on intermediate dispersion for the four treatment
groups (f) was 0.4. Detecting differences at the 5% level
with 80% power required 18 per group (72 patients in
total). Recruitment was slower than anticipated, and
when 58 patients had been recruited, the Data
Monitoring and Ethics Committee recommended that no
further patients were enrolled as a positive outcome ap-
peared increasingly unlikely.
Randomization and allocation concealment
Patients were randomly allocated to receive steroids
alone, steroids plus MTX, steroids plus ciclosporin, or
steroids plus MTX plus ciclosporin. Randomization was
stratified by centre, diagnosis (PM or DM) and by previous
treatment (ciclosporin or MTX). Randomization numbers
were assigned chronologically by centre after successful
screening. Metrologists and investigators were unaware
of the allocation sequence. Treatment assignments were
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in a locked cabinet in the coordinating centre pharmacy.
Trial medication (MTX and ciclosporin) and identical pla-
cebos were pre-packed in identical containers. They were
consecutively numbered for patients by centre according
to the randomization schedule. Each patient received
treatments in pre-packed containers.
Statistical methods
Data management and analyses used Stata (version 12.0,
StataCorp, College Station, TX, USA). Baseline character-
istics were summarized by randomized group. Descriptive
summary statistics were presented as mean (S.D.) for con-
tinuous normally distributed variables, as median and
interquartile range for other continuous variables, and as
frequency and percentage for categorical variables.
All participants had observations at baseline. Missing
follow-up data were imputed by multiple imputations
using multivariate normal regression, using an iterative
Markov chain Monte Carlo method to impute missing
values with 20 cycles. The 20 datasets were
combined using Rubin’s rules [911]. Estimates and
standard errors are presented as combined ones. A
linear mixed model was used to analyse the primary and
secondary outcomes. Random intercepts and slopes
were fitted for each patient, along with a random effect
of centre.
Intention-to-treat analyses were performed on the
imputed data from all randomized patients. Completer
analyses were performed on patients who completed 12
months. An interaction between treatment effects and
time was included. The estimates are presented as coef-
ficients with 95% CI; robust standard errors were used to
take account of the clustering effect of different geograph-
ical regions in the estimation of standard errors and
P-values. The estimates were adjusted for age, gender,
ethnicity, diagnosis (DM/ PM), and previous treatment
with MTX or ciclosporin. Statistical significance was deter-
mined at the 5% level using a two-sided P-value.
Results
A total of 369 patients were screened and 58 patients
were randomized. Screened patients who were not
randomized comprised 207 patients who did not meet
the inclusion criteria, 79 patients who did not consent
and 25 with only incomplete information about their dis-
ease. Twelve to sixteen patients were randomized to each
group (Fig. 1). Demography and baseline disease activity
assessments were similar for each group, as was previous
immunosuppressive treatment (supplementary Tables S2
and S3, available at Rheumatology Online).
Of the 58 randomized patients, 37 completed 12
months of treatment, 7 were lost to follow-up and 14 dis-
continued treatment. Of the latter, three patients withdrew
or stopped treatment due to disease progression, six due
to toxicity, four due to patient decision and one due to
other reasons. Mean (S.D.) doses of glucocorticoid admin-
istered during the trial was 26.77 (S.D. 23.38) mg.
In the patients who completed 12 months of treatment,
mean MMT increased from 64 to 73 (14% improvement),
WT decreased from 36 to 28 (22% improvement) and
FRS increased from 33 to 36 (9% improvement). These
changes were all significant on paired t-tests (P= 0.0001,
0.0064, 0.0009, respectively). Improvements over 12
months were correlated; for example, improvements in
FRS were related to improvements in MMT (Spearman’s
correlation 0.59) and WT (Spearman’s correlation 0.29).
Initial and final change scores for each group are shown in
supplementary Table S4, available at Rheumatology
Online.
There was no evidence of significant treatment effects
in either the intention-to-treat analysis (Table 1) or the
completer analysis (supplementary Table S5, available at
Rheumatology Online). In comparison with placebo ther-
apy, ciclosporin monotherapy, MTX monotherapy and
ciclosporinMTX combination therapy all showed no evi-
dence of significant benefits in unadjusted or adjusted
analyses. Furthermore, no significant main effects of
treatment were found when comparing MTX with MTX-
placebo or ciclosporin with ciclosporin-placebo (supple-
mentary Fig. S1, available at Rheumatology Online). There
was no evidence that immunosuppressive treatment
reduced glucocorticoid use: the mean daily prednisolone
dose at the end of the trial comprised 18 mg in the pla-
cebo group compared with 2226 mg in the various treat-
ment groups.
Adverse events were reported by 50 patients
(MTXciclosporin 12, MTX 10, ciclosporin 15, placebo
13), although only 14 withdrew because of this (Fig. 1).
The most commonly seen adverse events (>5% of
patients) comprised: musculoskeletal (MTXciclosporin
1, MTX 1, ciclosporin 1, placebo 2); gastrointestinal
(MTXciclosporin 4, MTX 4, placebo 5); and respiratory
(MTXciclosporin 3, MTX 2, ciclosporin 3, placebo 1).
Discussion
SELAM showed that MTX monotherapy, ciclosporin
monotherapy or ciclosporinMTX combination therapy)
improved disease activity in adult IIM patients with incom-
plete response to glucocorticoids. Continuing to use these
drugs in such patients is questionable. They have signifi-
cant toxicities in many rheumatic diseases without evi-
dence of efficacy in this clinical setting. Although IIM
patients enrolled in SELAM showed significant improve-
ments (922%) in key 12-month clinical outcomes, there
was no indication that immunosuppressive therapy influ-
enced these changes.
A recent study assessed prednisolone alone or com-
bined with MTX and ciclosporin in JDM. The times to in-
active disease and major therapeutic changes were less in
the combination groups compared with steroid monother-
apy [12]. However, both outcomes incorporated the phys-
ician’s opinion of disease activity and could be influenced
by the study’s open-label design; consequently, the find-
ings must be viewed with caution. The JDM study initiated
immunosuppressive therapy with steroids, whereas our
study assessed its efficacy in active disease despite ster-
oid therapy. It is possible that initial cytotoxic use may be
more effective than delayed treatment.
www.rheumatology.oxfordjournals.org 3
Second-line agents in myositis
SELAM has several potential limitations. First, as it was
placebo-controlled, clinicians may have been unwilling to
enrol patients with severe IIM. Only a minority of screened
patients were enrolled in SELAM. Although detailed infor-
mation on screen failures could not be collected for ethical
reasons, our clinical impression was that many were
taking additional MTX, ciclosporin or AZA that could not
be temporarily stopped. Secondly, the immunosuppres-
sive treatment may have been too conservative; more
intensive treatment might be effective. In addition, a few
FIG. 1 CONSORT flowchart for the SELAM trial
TABLE 1 Comparison of outcomes at 12 months between treatment groups in an intention-to-treat analysis
Unadjusted Adjusteda
Outcome Group Coefficients (95% CI) P-value Coefficients (95% CI) P-value
Manual muscle testing MTX/Ciclo 2.72 (8.60, 3.17) 0.365 1.02 (5.96, 3.92) 0.686
MTX 1.03 (4.88, 6.94) 0.732 0.17 (4.35, 4.69) 0.942
Ciclo 1.13 (7.50, 5.25) 0.729 0.42 (3.82, 4.66) 0.845
30-m walk MTX/Ciclo 5.03 (6.23, 16.29) 0.381 3.31 (6.79, 13.42) 0.520
MTX 6.95 (8.22, 22.12) 0.369 8.34 (3.35, 20.03) 0.162
Ciclo 8.21 (3.21, 19.63) 0.159 8.77 (1.22, 18.76) 0.085
Function, FRS MTX/Ciclo 1.91 (4.55, 0.74) 0.158 1.58 (4.06, 0.91) 0.214
MTX 2.04 (4.60, 0.52) 0.118 2.43 (4.92, 0.05) 0.055
Ciclo 1.43 (4.02, 1.16) 0.278 1.00 (3.39, 1.39) 0.412
Creatine phosphokinase MTX/Ciclo 426 (963, 111) 0.120 365 (793, 62) 0.094
MTX 455 (973, 62) 0.085 371 (756, 15) 0.060
Ciclo 360 (889, 170) 0.184 378 (859, 104) 0.124
ESR MTX/Ciclo 1.99 (11.77, 7.79) 0.69 3.04 (11.56, 5.49) 0.484
MTX 0.99 (12.03, 14.00) 0.882 0.78 (11.88, 13.44) 0.904
Ciclo 5.60 (4.37, 15.57) 0.271 5.09 (4.42, 14.60) 0.294
aAdjusted for age, gender, ethnicity and diagnosis (DM/PM); placebo is the reference group; Ciclo: ciclosporin; FRS: functional
rating scale.
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patients had received previous immunosuppressive ther-
apy, although as outlined in supplementary Table S2,
available at Rheumatology Online, this is unlikely to have
had a significant impact. Thirdly, the outcome measures
might have been too insensitive, particularly as SELAM
predated the standardization of IIM outcomes [13].
Fourthly, some muscle weakness may have been irrevers-
ible due to muscle damage or steroid myopathy. Fifthly,
treating all IIM patients similarly may be inappropriate, and
there may be different responses depending on patients’
autoantibody profiles [14]. Sixthly, Bohan and Peter’s cri-
teria have been used for over 35 years and alternative
criteria exist; using these might have identified patients
more likely to respond to immunosuppressive therapy.
Seventhly, only 37 of 58 patients (64%) completed 12
months of treatment; although withdrawals were not es-
pecially high for a 12-month placebo-controlled trial, they
might dilute the positive impacts of treatment. Finally, the
trial was relatively small and enrolment was stopped by
the Data Monitoring Committee (DMC) before the planned
sample size was reached. Small trials can miss treatment
effects in specific patient subgroups. Although the ab-
sence of evidence for an overall treatment effect makes
it unlikely that studying more patients would have chan-
ged the findings, alternative approaches to patient selec-
tion might have produced positive findings.
There is strong evidence that some additional treat-
ments benefit IIM patients who are incomplete responders
to glucocorticoids. Examples include IVIG [2] and creatine
supplements combined with intensive exercise [15].
Biologics like rituximab, despite initially promising results
[1618], have yet to deliver clear therapeutic benefits
when studied in RCTs [19]. The failure of conventional
immunosuppressives to benefit IIM patients who have in-
completely responded to glucocorticoids does not mean
that these agents are ineffective, only that the particular
treatment paradigm studied in SELAM appears inappro-
priate. Immunosuppressives could be effective as initial
combinations, although as some patients respond to ster-
oids alone the benefit of such an approach is uncertain.
Future research needs to identify effective treatments in
IIM patients who fail to respond to glucocorticoids and to
define optimal initial treatments. Potential novel treat-
ments include eculizumab [20] and abatacept (being eval-
uated in the ARTEMIS trial—http://clinicaltrials.gov/ct2/
show/NCT01315938). The negative results in SELAM
highlight the need for further RCTs in IIM.
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